This is a news story, published by CNBC, that relates primarily to Eisai news.
For more Eisai news, you can click here:
more Eisai newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
European drug regulators. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest European Medicines Agency news, drug regulator news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
treatment LeqembiCNBC
•83% Informative
Leqembi 's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine" Eisai said it is "extremely disappointed" by the regulator's negative recommendation.
Shares of Biogen fell nearly 7% in premarket trading Friday .
The U.S. Food and Drug Administration last year approved the drug.
VR Score
87
Informative language
91
Neutral language
18
Article tone
formal
Language
English
Language complexity
67
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links